On 24 September 2021, Mr. Paradorn Rangsimaporn, Chargé d'affaires, a.i., Royal Thai Embassy, Nur-Sultan, visited the Research Institute for Biological Safety Problems which developed and produced QazVac (or QazCovid-in), Kazakhstan’s own domestically developed COVID-19 vaccine, which uses the Inactivated Vaccine technology. QazVac had just finished its third phase of trials and found an effectiveness rate of approximately 90 percent from tests on more than 150,000 people. The Research Institute had already produced 1 million doses and plans to produce in total 3 million doses by the end of this year. It also has the maximum capacity to produce 60 million doses per year. The Research Institute is located in the Zhambyl region, approximately 180 km from Almaty. It was founded in 1958 and therefore has a lot of experience in research, development and production of around 70 products of vaccines and medicines used to protect and treat both humans and animals. The Research Institute is also in the process of developing 4 more COVID-19 vaccines, using various types of vaccine technology. It also expressed readiness to cooperate with Thailand upon request.